Item 5. Other Information
Item 5. Other Information
None .
53
Item 6. Exhibits
The following documents are filed as exhibits
to this Report.
EXHIBIT INDEX
Incorporated
by Reference
Exhibit No.
Description
Form
Exhibit
Filing
Date
2.1
Agreement
and Plan of Merger, dated July 16, 2025, by and among the Company, Ocuvex, and Onconetix Merger Sub, Inc.
8-K
2.1
July
16, 2025
2.2
Form
of Termination Agreement effective as of September 24, 2025, by and between the Company and Ocuvex Therapeutics, Inc.
8-K
10.4
September 26, 2025
3.1
Amended
and Restated Certificate of Incorporation
8-K
3.1
February 24,
2022
3.2
Certificate
of Amendment, dated April 24, 2023
8-K
3.1
April
24, 2023
3.3
Certificate
of Amendment, dated December 21, 2023
8-K
3.1
December
21, 2023
3.4
Certificate
of Amendment, dated September 24, 2024
8-K
3.1
September
24, 2024
3.5
Certificate
of Amendment, dated June 11, 2025
8-K
3.1
June
11, 2025
3.6
Certificate
of Designations authorizing the issuance of the Series C Preferred Stock
8-K
3.1
October
3, 2024
3.7
Certificate
of Correction to Certificate of Designations authorizing the issuance of the Series C Preferred Stock
10-Q
3.7
June
12, 2025
3.8
Fourth
Amended and Restated Bylaws of the Company
8-K
3.2
December
21, 2023
3.9
Certificate of Designation of Series D Preferred Stock.
8-K
3.1
September
26, 2025
3.10
Certificate of Designation of Series E Preferred Stock
8-K
3.1
October
3, 2025
4.1
Form
of Inducement PIO
8-K
4.1
July
11, 2024
4.2
Form of Warrant (Series C)
8-K
4.1
October
3, 2024
4.3
Form of Warrant (Series D)
8-K
4.1
September
26, 2025
4.4
Form of Warrant (Series E)
8-K
4.1
October
3, 2025
10.1
Note,
dated February 12, 2025
8-K
10.1
February
18, 2025
54
10.2
Note,
dated May 16, 2025
8-K
10.1
May
22, 2025
10.3
Note, dated June 5, 2025
8-K
10.1
June
11. 2025
10.4
Form
of Conversion Price Reduction Consent
8-K
10.3
July
16, 2025
10.5
Promissory
Note, dated August 6, 2025, by and between Keystone Capital Partners, LLC and the Company
8-K
10.1
August
12, 2025
10.6
Amended
and Restated Promissory Note, dated August 7, 2025, by and between Veru, Inc. and the Company
8-K
10.2
August
12, 2025
10.7
Settlement
Agreement and Release, dated September 22, 2025, by and between the Company and Veru, Inc.
8-K
10.3
September 26, 2025
10.8
Promissory
Note, dated August 28, 2025, by and between Keystone Capital Partners, LLC and the Company
8-K
10.1
September
4, 2025
10.9
Promissory
Note, dated August 28, 2025, by and between KCP Fund I, LLC and the Company
8-K
10.2
September
4, 2025
10.10
Second
Amended and Restated Promissory Note, dated August 28, 2025, by and between Veru, Inc. and the Company
8-K
10.3
September
4, 2025
10.11
Waiver,
dated August 28, 2025, by and between Veru, Inc. and the Company
8-K
10.4
September 4, 2025
10.12
License
Agreement, dated September 17, 2025, by and between Immunovia AB and Proteomedix AG
8-K
10.1
September
22, 2025
10.13
Form
of Securities Purchase Agreement dated September 22, 2025 relating to the sale of the Series D Preferred Stock and Warrants
8-K
10.1
September
26, 2025
10.14
Form
of Registration Rights Agreement dated as of September 22, 2025 relating to the resale of the shares of Common Stock underlying the
Series D Preferred Stock and Warrants
8-K
10.2
September
26, 2025
10.15
Settlement
Agreement and Release, dated September 22, 2025, by and between the Company and Veru, Inc.
8-K
10.3
September
26, 2025
10.16
Form
of Securities Purchase Agreement dated October 1, 2025 relating to the sale of the Series E Preferred Stock and Warrants
8-K
10.1
October
3, 2025
10.17
Form
of Registration Rights Agreement dated as of October 1, 2025 relating to the resale of the shares of Common Stock underlying the
Series E Preferred Stock and Warrants
8-K
10.2
October
3, 2025
31*
Certification of the Principal Financial Officer and Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32**
Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*
Inline
XBRL Instance Document.
101.SCH*
Inline
XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline
XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline
XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline
XBRL Taxonomy Extension Presentation Linkbase Document.
104*
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*
Filed herewith.
**
Furnished herewith.
55
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Onconetix, Inc.
Date: November 13, 2025
/s/ Karina M. Fedasz
Karina M. Fedasz
Interim Chief Executive Officer and
Interim Chief Financial Officer
(principal executive officer, and
principal financial and accounting officer)
56
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.